MARKET

RGNX

RGNX

Regenxbio
NASDAQ
13.28
+0.19
+1.45%
After Hours: 13.41 +0.13 +0.98% 19:50 07/02 EDT
OPEN
13.63
PREV CLOSE
13.09
HIGH
14.25
LOW
13.17
VOLUME
3.30M
TURNOVER
--
52 WEEK HIGH
16.19
52 WEEK LOW
5.46
MARKET CAP
686.54M
P/E (TTM)
-2.3757
1D
5D
1M
3M
1Y
5Y
1D
Regenxbio Chief Medical Officer Steve Pakola sells USD 695,992 of common shares
PUBT · 3d ago
Regenxbio Shares Rise on $100M Milestone Payment After First Patient Dosed in Eye-Disease Trial
Dow Jones · 3d ago
RegenXBio: Advancing Gene Therapy Pipeline and De-Risking Milestones Support Buy Rating and Unchanged $26 Price Target
TipRanks · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Regenxbio, Repay,  Natera, Fortune Brands
Reuters · 5d ago
BUZZ- Regenxbio rises on $100 million AbbVie milestone for eye disease drug
Reuters · 5d ago
Regenxbio Advances Diabetic Retinopathy Gene Therapy Trial
TipRanks · 5d ago
REGENXBIO Announces First Patient Dosed In Phase IIb/III NAAVIGATE Clinical Trial Of Investigational Surabgene Lomparvovec In Diabetic Retinopathy Using Suprachoroidal Delivery; REGENXBIO To Receive $100M From Abbvie For This Milestone
Benzinga · 5d ago
Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial
TipRanks · 5d ago
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.

Webull offers Regenxbio Inc stock information, including NASDAQ: RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.